SCWORX CORP (WORX)
US78396V2088 - Common Stock
Taking everything into account, WORX scores 1 out of 10 in our fundamental rating. WORX was compared to 37 industry peers in the Health Care Technology industry. Both the profitability and financial health of WORX have multiple concerns. WORX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
WORX had negative earnings in the past year.
In the past year WORX has reported a negative cash flow from operations.
WORX had negative earnings in each of the past 5 years.
In the past 5 years WORX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -53.81%, WORX is doing worse than 74.29% of the companies in the same industry.
Looking at the Return On Equity, with a value of -78.26%, WORX is doing worse than 62.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.81% | ||
| ROE | -78.26% | ||
| ROIC | N/A |
ROA(3y)-41.73%
ROA(5y)-61.6%
ROE(3y)-63.35%
ROE(5y)-96.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
WORX has a Gross Margin of 28.98%. This is amonst the worse of the industry: WORX underperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of WORX has remained more or less at the same level.
WORX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5YN/A
2. Health
2.1 Basic Checks
WORX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, WORX has more shares outstanding
Compared to 5 years ago, WORX has more shares outstanding
The debt/assets ratio for WORX has been reduced compared to a year ago.
2.2 Solvency
WORX has an Altman-Z score of -5.88. This is a bad value and indicates that WORX is not financially healthy and even has some risk of bankruptcy.
WORX has a worse Altman-Z score (-5.88) than 82.86% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that WORX is not too dependend on debt financing.
WORX's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. WORX outperforms 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.88 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
A Current Ratio of 0.33 indicates that WORX may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.33, WORX is doing worse than 91.43% of the companies in the same industry.
WORX has a Quick Ratio of 0.33. This is a bad value and indicates that WORX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.33, WORX is doing worse than 91.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.33 | ||
| Quick Ratio | 0.33 |
3. Growth
3.1 Past
The earnings per share for WORX have decreased strongly by -65.42% in the last year.
Looking at the last year, WORX shows a very negative growth in Revenue. The Revenue has decreased by -17.96% in the last year.
The Revenue has been growing by 90.92% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-65.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.16%
Revenue 1Y (TTM)-17.96%
Revenue growth 3Y-9.95%
Revenue growth 5Y90.92%
Sales Q2Q%-16.51%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
WORX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
WORX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCWORX CORP
NASDAQ:WORX (1/3/2025, 8:10:44 PM)
After market: 1.99 +0.01 (+0.51%)1.98
+0.25 (+14.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners8.04%
Inst Owner Change-89.38%
Ins Owners4.5%
Ins Owner Change0%
Market Cap3.68M
Analysts0
Price TargetN/A
Short Float %2.16%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.14 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.82 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.8
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS1.73
BVpS2.41
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.81% | ||
| ROE | -78.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.98% | ||
| FCFM | N/A |
ROA(3y)-41.73%
ROA(5y)-61.6%
ROE(3y)-63.35%
ROE(5y)-96.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5YN/A
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.33 | ||
| Quick Ratio | 0.33 | ||
| Altman-Z | -5.88 |
F-Score4
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.16%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.96%
Revenue growth 3Y-9.95%
Revenue growth 5Y90.92%
Sales Q2Q%-16.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y44.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.95%
OCF growth 3YN/A
OCF growth 5YN/A